Two of Europe’s gene therapy pioneers have reported significant progress in the last week, bringing commercial gene therapy products yet closer to reality.
Nanotechnology is beginning to leave the laboratory and hit the high street – but health scares could stop this commercialisation process in its tracks.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and the fortnightly R&D Express, tracking reforms and investments in central and eastern Europe.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.